- Home
- VSTM vs MAIA Comparison
VSTM vs MAIA Comparison
Compare VSTM & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTM | MAIA |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.8M | 49.3M |
| IPO Year | 2012 | 2022 |
Fundamental Metrics
Financial Performance| Metric | VSTM | MAIA |
|---|---|---|
| Price | $7.73 | $1.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $13.38 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 865.2K |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,379,000.00 | N/A |
| Revenue This Year | $208.54 | N/A |
| Revenue Next Year | $251.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.79 | N/A |
| 52 Week Low | $3.46 | $0.87 |
| 52 Week High | $11.25 | $2.74 |
Technical Indicators
Market Signals| Indicator | VSTM | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 37.70 | 59.05 |
| Support Level | $7.59 | $1.33 |
| Resistance Level | $8.14 | $1.64 |
| Average True Range (ATR) | 0.53 | 0.17 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 11.33 | 64.77 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.